m6A modification-related gene polymorphisms

This research examined 5 single nucleotide polymorphisms (SNPs) related to m6A modification in 148 patients with diffuse large B-cell lymphoma (DLBCL) and 222 healthy controls, including ALKBH5 rs8400, YTHDC2 rs6594732, METTL14 rs298982, METTL14 rs1064034 and METTL14 rs62328061. This data specifically included the clinical characteristics and SNPs information of the patients and the control group, and has been encoded to protect personal privacy. In detail, Sex 0 refers to female, 1 refers to male; Age 0 refers to <60 yeas old, 1 refers to ≥60 yeas old; B symbol 0 refers to no,1 refers to yes; ECOG 0 refers to <2 scores, 1 refers to ≥2 scores; Ann Arbor 0 refers to I/II stage, 1 refers to III/IV stage; IPI 0 refers to 0-2 scores, 1 refers to 3-5 scores; WBC count 0 refers to <10×10^9/L, 1 refers to ≥10×10^9/L; HGB count 0 refers to ≥120g/L, 1 refers to <120g/L; PLT count 0 refers to ≥100×10^9/L, 1 refers to <100×10^9/L; CR 0 refers to no CR, 1 refers to CR; Status 0 refers to alive, 1 refers to dead. This study aimed to explore the influence of m6A modification-related SNPs on the susceptibility, WBC count, risk stratification, treatment response and survival prognosis of DLBCL by analyzing the above clinical characteristics and SNP genotypes.